1-(3-bromobenzyl)-3-methylazulene | 655237-28-8

• 分子结构分类: 有机化合物 - 碳氢化合物 - 不饱和烃
• 英文名称: 1-(3-bromobenzyl)-3-methylazulene
• 英文别名: 1-[(3-bromophenyl)methyl]-3-methylazulene
• CAS: 655237-28-8
• 化学式: C₁₈H₁₅Br
• 分子量: 311.221
• InChiKey: IWUNCZPVRNIEEH-UHFFFAOYSA-N

物化性质

• 沸点：
  425.3±14.0 °C(Predicted)
• 密度：
  1.322±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(3-bromobenzyl)-3-methylazulene 在 正丁基锂 、 三异丙基硅烷 、 三氟化硼乙醚 作用下， 以 四氢呋喃 、 正己烷 、 乙腈 为溶剂， 反应 4.0h， 生成 (1S)-2,3,4,6-tetra-O-benzyl-1,5-anhydro-1-{3-[(3-methylazulen-1-yl)methyl]phenyl}-D-glucitol
  参考文献：
  名称：

  Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543

  摘要：

  Here, a series of C-glucosides with azulene rings in the aglycon moiety was synthesized and the inhibitory activities toward hSGLT1 and hSGLT2 were evaluated. Starting from the azulene derivative 7 which had relatively good SGLT2 inhibitory activity, compound 8a which has a 3-[(azulen-2-yl)methyl]phenyl group was identified as a lead compound for further optimization. Introduction of a phenolic hydroxyl group onto the central benzene ring afforded a potent and selective SGLT2 inhibitor 8e, which reduced blood glucose levels in a dose-dependent manner in rodent diabetic models. A mono choline salt of 8e (YM543) was selected as a clinical candidate for use in treating type 2 diabetes mellitus. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.03.067
• 作为产物：
  描述：

  3-溴苯甲酰氯 在 aluminum (III) chloride 、 sodium tetrahydroborate 、 三氟化硼乙醚 作用下， 以 乙醚 、 二氯甲烷 、 二乙二醇二甲醚 为溶剂， 反应 2.25h， 生成 1-(3-bromobenzyl)-3-methylazulene
  参考文献：
  名称：

  Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543

  摘要：

  Here, a series of C-glucosides with azulene rings in the aglycon moiety was synthesized and the inhibitory activities toward hSGLT1 and hSGLT2 were evaluated. Starting from the azulene derivative 7 which had relatively good SGLT2 inhibitory activity, compound 8a which has a 3-[(azulen-2-yl)methyl]phenyl group was identified as a lead compound for further optimization. Introduction of a phenolic hydroxyl group onto the central benzene ring afforded a potent and selective SGLT2 inhibitor 8e, which reduced blood glucose levels in a dose-dependent manner in rodent diabetic models. A mono choline salt of 8e (YM543) was selected as a clinical candidate for use in treating type 2 diabetes mellitus. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.03.067

文献信息

• Azulene derivatives and salts thereof
  申请人：Tomiyama Hiroshi

  公开号：US20050124555A1

  公开（公告）日：2005-06-09

  The present invention provides an azulene derivative and a salt thereof, wherein an azulene ring is bonded to a benzene ring directly or via a lower alkylene which may be substituted with a halogen atom and the benzene ring is directly bonded to the glucose residue, and it is usable as a Na + -glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes-related diseases such as insulin-resistant diseases and obesity.

  本发明提供了一种吲哚蓝衍生物及其盐，其中吲哚蓝环直接或通过可被取代为卤原子的较低烷基与苯环结合，苯环直接与葡萄糖残基结合，可用作Na+-葡萄糖共转运蛋白抑制剂，特别用于治疗和/或预防糖尿病，如胰岛素依赖型糖尿病（1型糖尿病）和胰岛素非依赖型糖尿病（2型糖尿病），以及糖尿病相关疾病，如胰岛素抵抗性疾病和肥胖症。
• AZULENE DERIVATIVES AND SALTS THEREOF
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP1553094A1

  公开（公告）日：2005-07-13

  The present invention provides an azulene derivative and a salt thereof, wherein an azulene ring is bonded to a benzene ring directly or via a lower alkylene which may be substituted with a halogen atom and the benzene ring is directly bonded to the glucose residue, and it is usable as a Na+-glucose cotransporter inhibitor, especially for a therapeutic and/or preventive agent for diabetes such as insulin-dependent diabetes (type 1 diabetes) and insulin-independent diabetes (type 2 diabetes), as well as diabetes-related diseases such as insulin-resistant diseases and obesity.

  本发明提供了一种偶氮烯衍生物及其盐，其中偶氮烯环直接或通过可被卤原子取代的低级亚烷基与苯环键合，苯环直接与葡萄糖残基键合、可用作 Na+-葡萄糖共转运体抑制剂，特别是用于治疗和/或预防糖尿病，如胰岛素依赖型糖尿病（1 型糖尿病）和胰岛素非依赖型糖尿病（2 型糖尿病），以及与糖尿病相关的疾病，如胰岛素抵抗性疾病和肥胖症。
• US7169761B2
  申请人：——

  公开号：US7169761B2

  公开（公告）日：2007-01-30